CD8A and myelodysplastic syndrome: Having observed a gradual increase in the frequency of the CD57+CXCR3+CD8+ T-cell subset from LR-MDS to AML, we next assessed whether the proportion of this cell population before AZA treatment initiation was associated with response to treatment.